<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777097</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00123</org_study_id>
    <nct_id>NCT04777097</nct_id>
  </id_info>
  <brief_title>Blood Loss and Preeclampsia</brief_title>
  <official_title>Does Preeclampsia Affect Blood Loss During a Caesarean Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of blood loss in preeclamptic patients using mathematical formulae&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-eclampsia is a symptom complex that occurs in 2-5% of all pregnancies and leads to&#xD;
      significant morbidity and mortality. It is associated with a risk of impaired coagulation&#xD;
      caused by a reduced platelet count, very rarely by disseminated intravascular coagulation&#xD;
      disorders. The degree of clotting correlates with the severity of preeclampsia. It is planned&#xD;
      to calculate the blood loss using mathematical formulas and to compare the different blood&#xD;
      loss in the two groups (preeclampsia vs. healthy pregnant women). Furthermore, this project&#xD;
      will try to correlate the blood loss with the underlying coagulation situation. The aim is to&#xD;
      be able to better assess the bleeding risk in healthy pregnant women, but also in&#xD;
      pre-eclamptic patients in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood-Loss</measure>
    <time_frame>day 1</time_frame>
    <description>Corelation between blood loss and coagulation parameters will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameter</measure>
    <time_frame>day 1</time_frame>
    <description>Impact of pre-eclampsia on the coagulation parameters</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pre-Eclampsia; Complicating Pregnancy</condition>
  <condition>Blood Loss</condition>
  <condition>Coagulation Disorder</condition>
  <arm_group>
    <arm_group_label>healthy pregnant women</arm_group_label>
    <description>Healthy patients who receive a cesarean operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-eclampsia</arm_group_label>
    <description>Patients with pre-eclampsia who receive a caesarean operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Two blood sample will be drawn. On the day of operation and the first postoperative day.</description>
    <arm_group_label>Pre-eclampsia</arm_group_label>
    <arm_group_label>healthy pregnant women</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pre-eclampsia planed for cesarean section vs. healty pregnant women, planmned&#xD;
        for cesarean section&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective or urgent caesarean section&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency caesarean section&#xD;
&#xD;
          -  Familial coagulation disorder&#xD;
&#xD;
          -  Hematological disorders that affect the platelet count, e.g. myelodysplastic syndrome&#xD;
             (MDS)&#xD;
&#xD;
          -  Taking anticoagulants&#xD;
&#xD;
          -  Taking aspirin in the last 14 days&#xD;
&#xD;
          -  Use of NSARs in the last 24 hours&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marco P Zalunardo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut of Anesthesiology University Hospital Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco P Zalunardo, Prof</last_name>
    <phone>+41442552695</phone>
    <email>marco.zalunardo@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donat R Spahn, Prof</last_name>
    <phone>+41442552695</phone>
    <email>donat.spahn@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Institute for Anesthesiology</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco P Zalunardo, Prof</last_name>
      <phone>+41442552695</phone>
      <email>marco.zalunardo@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Donat R Spahn, Prof</last_name>
      <phone>+41442552695</phone>
      <email>donat.spahn@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Schläpfer, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997 Oct;37(10):1070-4.</citation>
    <PMID>9354828</PMID>
  </results_reference>
  <results_reference>
    <citation>Theusinger OM, Kind SL, Seifert B, Borgeat L, Gerber C, Spahn DR. Patient blood management in orthopaedic surgery: a four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland. Blood Transfus. 2014 Apr;12(2):195-203. doi: 10.2450/2014.0306-13.</citation>
    <PMID>24931841</PMID>
  </results_reference>
  <results_reference>
    <citation>de Lange NM, Lancé MD, de Groot R, Beckers EA, Henskens YM, Scheepers HC. Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv. 2012 Jul;67(7):426-35. doi: 10.1097/OGX.0b013e3182605861. Review.</citation>
    <PMID>22926249</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-eclampsia</keyword>
  <keyword>blood-loss</keyword>
  <keyword>impaired coagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

